Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Key Highlights
- ➤9 of 14 patients remained in clinical remission 52 weeks after one EP-104GI administration
- ➤Cohort 9 maintained 66% clinical remission at 52 weeks
- ➤Cohort 8b EoEHSS Stage and Grade reductions reached -0.26 and -0.27 at 36 weeks
- ➤Phase 2b interim data expected in December 2026
- ➤No treatment-related SAEs, adrenal insufficiency, glucose derangement, or oropharyngeal candidiasis reported
Expert Statements
Dr. James Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals
“The 52-week and 36-week data from the highest dosing cohorts of the Phase 1b/2a RESOLVE trial further strengthen the observed durable treatment effects of EP-104GI in EoE patients.”
Dr. James Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals
“In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements.”
Dr. James Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals
“If achieved, an annual dosing regimen could align well with ACG Guidelines supporting routine endoscopic monitoring of EoE patients.”
Dr. Jeymi Tambiah, Chief Medical Officer of Eupraxia Pharmaceuticals
“These encouraging efficacy and durability data suggest that EP-104GI may have the potential to treat patients suffering with EoE with a single annual dose.”
Dr. Jeymi Tambiah, Chief Medical Officer of Eupraxia Pharmaceuticals
“We have not observed any treatment-related Serious Adverse Events (SAEs) to date or adverse events related to corticosteroid exposure, such as abnormal changes to glucose levels.”
Dr. Jeymi Tambiah, Chief Medical Officer of Eupraxia Pharmaceuticals
“Oropharyngeal Candidiasis has not been observed in any of the 10 cohorts to date.”
* The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission(1) * The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at 36 weeks * The Cohort 8b and Cohort 9 responses are consistent with clinical and histologic responses seen across all cohorts analyzed to date; in total, 9 of 14 patients (64%) have remained in clinical remission 52 weeks after receiving a single administration of EP-104GI VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”).
Get started
Create a free account to read the full story.